| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2019 | 815 | 1.200 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2025 | 194 | 0.980 |
Why?
|
| Methotrexate | 2 | 2025 | 351 | 0.900 |
Why?
|
| Drug Monitoring | 1 | 2025 | 175 | 0.830 |
Why?
|
| Hemangioendothelioma | 2 | 2022 | 25 | 0.800 |
Why?
|
| Vascular Malformations | 2 | 2022 | 112 | 0.720 |
Why?
|
| Medical Oncology | 4 | 2018 | 244 | 0.510 |
Why?
|
| Hyperglycemia | 2 | 2009 | 235 | 0.510 |
Why?
|
| Patient Rights | 1 | 2014 | 51 | 0.410 |
Why?
|
| Treatment Refusal | 1 | 2014 | 80 | 0.410 |
Why?
|
| Hodgkin Disease | 3 | 2012 | 304 | 0.390 |
Why?
|
| Hospitals | 1 | 2015 | 439 | 0.380 |
Why?
|
| Lymphatic Abnormalities | 3 | 2021 | 36 | 0.350 |
Why?
|
| Patient Discharge | 1 | 2015 | 511 | 0.350 |
Why?
|
| Informed Consent | 1 | 2014 | 346 | 0.350 |
Why?
|
| Education, Continuing | 1 | 2010 | 32 | 0.340 |
Why?
|
| Career Choice | 2 | 2011 | 160 | 0.320 |
Why?
|
| Chylothorax | 2 | 2021 | 28 | 0.320 |
Why?
|
| Societies, Medical | 2 | 2011 | 778 | 0.310 |
Why?
|
| Thrombocytopenia | 3 | 2021 | 233 | 0.310 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2005 | 66 | 0.280 |
Why?
|
| Cholestasis | 1 | 2008 | 157 | 0.260 |
Why?
|
| Hematology | 3 | 2018 | 41 | 0.240 |
Why?
|
| Neoplasm Proteins | 3 | 2005 | 702 | 0.240 |
Why?
|
| Child | 20 | 2025 | 25783 | 0.240 |
Why?
|
| Costa Rica | 1 | 2025 | 15 | 0.230 |
Why?
|
| Physicians | 2 | 2016 | 640 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 570 | 0.230 |
Why?
|
| Algorithms | 2 | 2025 | 1725 | 0.230 |
Why?
|
| Child, Preschool | 14 | 2025 | 14736 | 0.220 |
Why?
|
| Humans | 45 | 2025 | 132247 | 0.220 |
Why?
|
| Infusions, Intravenous | 2 | 2025 | 547 | 0.220 |
Why?
|
| U937 Cells | 2 | 2001 | 23 | 0.210 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 120 | 0.190 |
Why?
|
| Sirolimus | 2 | 2021 | 241 | 0.190 |
Why?
|
| Hemangioma | 1 | 2023 | 97 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 1348 | 0.190 |
Why?
|
| Antigens, CD | 2 | 2001 | 436 | 0.190 |
Why?
|
| Receptors, IgE | 1 | 2001 | 11 | 0.180 |
Why?
|
| Hepatoblastoma | 3 | 2009 | 183 | 0.180 |
Why?
|
| Antigens, CD20 | 1 | 2001 | 40 | 0.180 |
Why?
|
| Angiomatosis | 1 | 2021 | 6 | 0.180 |
Why?
|
| Infant | 10 | 2025 | 13049 | 0.170 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 36 | 0.170 |
Why?
|
| Pleural Effusion | 1 | 2021 | 110 | 0.170 |
Why?
|
| Adolescent | 13 | 2025 | 20557 | 0.170 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 3093 | 0.170 |
Why?
|
| Human Genome Project | 1 | 2000 | 56 | 0.170 |
Why?
|
| Genetics, Medical | 1 | 2001 | 121 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2021 | 145 | 0.160 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2000 | 37 | 0.160 |
Why?
|
| Remission Induction | 3 | 2011 | 306 | 0.160 |
Why?
|
| Thyroiditis, Suppurative | 1 | 2019 | 5 | 0.160 |
Why?
|
| Thyroid Crisis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 311 | 0.160 |
Why?
|
| Male | 20 | 2025 | 65014 | 0.160 |
Why?
|
| Candida tropicalis | 1 | 2019 | 17 | 0.160 |
Why?
|
| Female | 22 | 2025 | 70787 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2001 | 202 | 0.150 |
Why?
|
| Prednisone | 2 | 2009 | 253 | 0.140 |
Why?
|
| Peritoneovenous Shunt | 1 | 2018 | 5 | 0.140 |
Why?
|
| Candidiasis | 1 | 2019 | 137 | 0.140 |
Why?
|
| Vincristine | 2 | 2009 | 196 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2005 | 1683 | 0.140 |
Why?
|
| Chylous Ascites | 1 | 2017 | 11 | 0.140 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 2018 | 28 | 0.140 |
Why?
|
| Genome | 1 | 2000 | 504 | 0.140 |
Why?
|
| Gene Expression | 2 | 2014 | 1563 | 0.130 |
Why?
|
| Ascites | 1 | 2018 | 103 | 0.130 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 1381 | 0.130 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 45 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 673 | 0.130 |
Why?
|
| Pediatrics | 3 | 2018 | 1210 | 0.130 |
Why?
|
| Career Mobility | 1 | 2016 | 52 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 897 | 0.120 |
Why?
|
| Drainage | 1 | 2017 | 262 | 0.120 |
Why?
|
| Prognosis | 5 | 2018 | 5016 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 277 | 0.120 |
Why?
|
| Human Rights Abuses | 1 | 2015 | 1 | 0.120 |
Why?
|
| Patient Advocacy | 1 | 2015 | 63 | 0.120 |
Why?
|
| Macrophages | 1 | 2000 | 692 | 0.120 |
Why?
|
| Organizational Policy | 1 | 2015 | 53 | 0.120 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2014 | 36 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2009 | 1121 | 0.110 |
Why?
|
| Israel | 1 | 2014 | 48 | 0.110 |
Why?
|
| Anemia | 1 | 2018 | 350 | 0.110 |
Why?
|
| Mental Competency | 1 | 2014 | 53 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2015 | 232 | 0.100 |
Why?
|
| Genomics | 1 | 2001 | 1652 | 0.100 |
Why?
|
| Emergencies | 1 | 2014 | 186 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2002 | 551 | 0.100 |
Why?
|
| Quality of Life | 1 | 2022 | 2161 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 520 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 146 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 611 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2003 | 146 | 0.090 |
Why?
|
| Wnt Proteins | 2 | 2009 | 224 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 99 | 0.090 |
Why?
|
| Risk Adjustment | 1 | 2011 | 55 | 0.090 |
Why?
|
| Global Health | 1 | 2015 | 643 | 0.080 |
Why?
|
| Physicians, Women | 1 | 2011 | 52 | 0.080 |
Why?
|
| RNA, Messenger | 6 | 2003 | 2680 | 0.080 |
Why?
|
| Job Satisfaction | 1 | 2010 | 99 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 178 | 0.080 |
Why?
|
| Monocytes | 2 | 2002 | 342 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 1883 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2018 | 380 | 0.080 |
Why?
|
| Daunorubicin | 1 | 2009 | 27 | 0.080 |
Why?
|
| Mechlorethamine | 1 | 2008 | 7 | 0.080 |
Why?
|
| Asparaginase | 1 | 2009 | 49 | 0.080 |
Why?
|
| Procarbazine | 1 | 2008 | 12 | 0.080 |
Why?
|
| Minority Groups | 1 | 2011 | 250 | 0.070 |
Why?
|
| Vinblastine | 1 | 2008 | 57 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 1294 | 0.070 |
Why?
|
| Bleomycin | 1 | 2008 | 113 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 2166 | 0.070 |
Why?
|
| Radiotherapy Dosage | 1 | 2008 | 237 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 899 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2009 | 273 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2008 | 303 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 1365 | 0.070 |
Why?
|
| Membrane Proteins | 4 | 2009 | 1597 | 0.070 |
Why?
|
| Recurrence | 2 | 2011 | 1453 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2009 | 387 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2023 | 13027 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17395 | 0.060 |
Why?
|
| HIV Infections | 1 | 2018 | 2049 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2003 | 454 | 0.060 |
Why?
|
| Syndrome | 1 | 2008 | 1175 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2018 | 3139 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2005 | 64 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 451 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 1285 | 0.060 |
Why?
|
| Mice | 2 | 2011 | 18509 | 0.060 |
Why?
|
| Leukemia | 2 | 2005 | 372 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2005 | 241 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2002 | 1965 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2001 | 3046 | 0.060 |
Why?
|
| Neoplasms | 2 | 2018 | 2961 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 387 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2001 | 1045 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 188 | 0.050 |
Why?
|
| DNA, Concatenated | 1 | 2003 | 5 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 811 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 249 | 0.050 |
Why?
|
| Time Factors | 1 | 2014 | 6451 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2009 | 995 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2003 | 311 | 0.050 |
Why?
|
| Propranolol | 1 | 2023 | 112 | 0.050 |
Why?
|
| Spectral Karyotyping | 1 | 2002 | 8 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2011 | 2491 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2001 | 140 | 0.050 |
Why?
|
| Chromosomes, Human | 1 | 2002 | 130 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 1304 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 223 | 0.050 |
Why?
|
| Octreotide | 1 | 2021 | 24 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 72 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 2000 | 252 | 0.050 |
Why?
|
| Acute Disease | 2 | 2002 | 1163 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2001 | 27 | 0.040 |
Why?
|
| Ligases | 1 | 2001 | 40 | 0.040 |
Why?
|
| Ubiquitins | 1 | 2001 | 43 | 0.040 |
Why?
|
| Prevalence | 1 | 2008 | 2664 | 0.040 |
Why?
|
| Azathioprine | 1 | 2001 | 38 | 0.040 |
Why?
|
| Embolism, Air | 1 | 2001 | 24 | 0.040 |
Why?
|
| Endothelium, Lymphatic | 1 | 2021 | 9 | 0.040 |
Why?
|
| Novobiocin | 1 | 1981 | 2 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1981 | 15 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 127 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2001 | 81 | 0.040 |
Why?
|
| Risk Factors | 4 | 2018 | 10945 | 0.040 |
Why?
|
| Pregnancy | 1 | 2014 | 7557 | 0.040 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2021 | 16 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2001 | 72 | 0.040 |
Why?
|
| Simplexvirus | 1 | 1981 | 100 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 3995 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 543 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 651 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 2669 | 0.040 |
Why?
|
| Methyltransferases | 1 | 2001 | 82 | 0.040 |
Why?
|
| Base Sequence | 2 | 2002 | 2900 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 1555 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2000 | 53 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2001 | 140 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 2000 | 213 | 0.040 |
Why?
|
| Acetyltransferases | 1 | 2000 | 77 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 2314 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2000 | 109 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 421 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2002 | 3771 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 2552 | 0.040 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 131 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2014 | 380 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2001 | 192 | 0.040 |
Why?
|
| DNA, Viral | 1 | 1981 | 492 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 1829 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 9966 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2014 | 650 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2019 | 102 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2001 | 189 | 0.040 |
Why?
|
| Cunninghamella | 1 | 1998 | 3 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 1423 | 0.040 |
Why?
|
| Botswana | 1 | 2018 | 76 | 0.040 |
Why?
|
| Lung Diseases, Fungal | 1 | 1998 | 37 | 0.040 |
Why?
|
| Mucormycosis | 1 | 1998 | 32 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 1718 | 0.040 |
Why?
|
| Adult | 5 | 2021 | 31614 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2018 | 100 | 0.030 |
Why?
|
| Peritoneum | 1 | 2017 | 41 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 1803 | 0.030 |
Why?
|
| Doxycycline | 1 | 2018 | 121 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2000 | 364 | 0.030 |
Why?
|
| Aged | 2 | 2018 | 21482 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 618 | 0.030 |
Why?
|
| Bacteremia | 1 | 2001 | 428 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 208 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2017 | 153 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2021 | 8548 | 0.030 |
Why?
|
| Middle Aged | 2 | 2018 | 29021 | 0.030 |
Why?
|
| DNA | 1 | 1981 | 1479 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2009 | 881 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1671 | 0.030 |
Why?
|
| HIV-1 | 1 | 2018 | 484 | 0.030 |
Why?
|
| Genome, Human | 1 | 2001 | 1331 | 0.030 |
Why?
|
| Contrast Media | 1 | 2018 | 507 | 0.030 |
Why?
|
| Animals | 4 | 2011 | 34854 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 1134 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 262 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 545 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2014 | 596 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2014 | 673 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 794 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 167 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2009 | 2062 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 170 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 134 | 0.020 |
Why?
|
| Cell Division | 2 | 2001 | 744 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 761 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 956 | 0.020 |
Why?
|
| Transcription Factor HES-1 | 1 | 2009 | 18 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5410 | 0.020 |
Why?
|
| Sarcoma | 1 | 1991 | 207 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2009 | 27 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2009 | 39 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2011 | 1997 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1102 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 6568 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 333 | 0.020 |
Why?
|
| beta Catenin | 1 | 2009 | 227 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2009 | 296 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 294 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 309 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2009 | 212 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 86 | 0.020 |
Why?
|
| Alleles | 1 | 1991 | 1685 | 0.020 |
Why?
|
| Glioma | 1 | 1991 | 535 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 607 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2007 | 120 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 608 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2139 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3853 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 569 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 76 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2005 | 286 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 685 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2003 | 35 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 136 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 2003 | 104 | 0.010 |
Why?
|
| Artificial Gene Fusion | 1 | 2002 | 12 | 0.010 |
Why?
|
| PAX5 Transcription Factor | 1 | 2002 | 15 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2002 | 140 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 295 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 636 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2002 | 58 | 0.010 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Anaphase-Promoting Complex-Cyclosome | 1 | 2001 | 20 | 0.010 |
Why?
|
| Home Nursing | 1 | 2001 | 13 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2001 | 31 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1797 | 0.010 |
Why?
|
| Oxolinic Acid | 1 | 1981 | 1 | 0.010 |
Why?
|
| Aminocoumarins | 1 | 1981 | 1 | 0.010 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2001 | 39 | 0.010 |
Why?
|
| Nalidixic Acid | 1 | 1981 | 3 | 0.010 |
Why?
|
| Coumarins | 1 | 1981 | 23 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2001 | 56 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 774 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 358 | 0.010 |
Why?
|
| Cricetinae | 1 | 1981 | 381 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 1045 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 2001 | 141 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 3358 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 590 | 0.010 |
Why?
|
| Pyrroles | 1 | 1981 | 182 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 686 | 0.010 |
Why?
|
| Radiography | 1 | 2001 | 818 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2001 | 375 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 623 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2002 | 813 | 0.010 |
Why?
|
| Virus Replication | 1 | 1981 | 636 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 1998 | 148 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1757 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1998 | 308 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3414 | 0.010 |
Why?
|
| Survivors | 1 | 1998 | 358 | 0.010 |
Why?
|
| Cell Line | 1 | 1981 | 2724 | 0.010 |
Why?
|
| United States | 1 | 2011 | 11669 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 1177 | 0.010 |
Why?
|
| Genotype | 1 | 2001 | 2703 | 0.010 |
Why?
|
| Hospitalization | 1 | 2001 | 1902 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1991 | 19 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 4540 | 0.010 |
Why?
|
| Mutation | 1 | 2001 | 6250 | 0.000 |
Why?
|